PH12014501231A1 - Transdermal delivery system comprising buprenorphine - Google Patents
Transdermal delivery system comprising buprenorphineInfo
- Publication number
- PH12014501231A1 PH12014501231A1 PH12014501231A PH12014501231A PH12014501231A1 PH 12014501231 A1 PH12014501231 A1 PH 12014501231A1 PH 12014501231 A PH12014501231 A PH 12014501231A PH 12014501231 A PH12014501231 A PH 12014501231A PH 12014501231 A1 PH12014501231 A1 PH 12014501231A1
- Authority
- PH
- Philippines
- Prior art keywords
- buprenorphine
- sensitive adhesive
- adhesive layer
- acid
- pressure
- Prior art date
Links
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 title abstract 8
- 229960001736 buprenorphine Drugs 0.000 title abstract 8
- 230000037317 transdermal delivery Effects 0.000 title 1
- 239000010410 layer Substances 0.000 abstract 5
- 239000004820 Pressure-sensitive adhesive Substances 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 abstract 2
- 239000012790 adhesive layer Substances 0.000 abstract 2
- 150000001735 carboxylic acids Chemical class 0.000 abstract 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 abstract 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 abstract 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 abstract 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 abstract 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000005642 Oleic acid Substances 0.000 abstract 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 abstract 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 abstract 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 abstract 1
- 229940040102 levulinic acid Drugs 0.000 abstract 1
- 235000020778 linoleic acid Nutrition 0.000 abstract 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 abstract 1
- 229960004232 linoleic acid Drugs 0.000 abstract 1
- 229960004488 linolenic acid Drugs 0.000 abstract 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 abstract 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 abstract 1
- 235000021313 oleic acid Nutrition 0.000 abstract 1
- 229960002969 oleic acid Drugs 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self- adhesive layer structure comprising A) a buprenofhine-impermeable backing layer, and B) a buprenorphine-containing pressure-sensitive adhesive layer on said buprenorphine-impermeable backing layer, the adhesive layer comprising a) at least one polymer-based pressure-sensitive adhesive, b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, and c) a carboxylic acid selected from the group consisting of oleic acid, linoleic acid and linolenic acid, levulinic acid and mixtures thereof, in an amount sufficient so that said analgesically effective amount of buprenorphine is solubilized therein to form a mixture, and the carboxylic acid buprenorphine mixture forms dispersed deposits in the said pressure-sensitive adhesive, wherein said buprenorphine-containing pressure-sensitive adhesive layer is the skin contact layer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161569609P | 2011-12-12 | 2011-12-12 | |
| PCT/IB2012/002973 WO2013088254A1 (en) | 2011-12-12 | 2012-12-12 | Transdermal delivery system comprising buprenorphine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12014501231A1 true PH12014501231A1 (en) | 2014-09-08 |
Family
ID=47754872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12014501231A PH12014501231A1 (en) | 2011-12-12 | 2014-05-30 | Transdermal delivery system comprising buprenorphine |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US20140363487A1 (en) |
| EP (1) | EP2790685B1 (en) |
| JP (2) | JP6289378B2 (en) |
| KR (1) | KR102014565B1 (en) |
| CN (2) | CN104114161A (en) |
| AP (1) | AP4036A (en) |
| AR (1) | AR089201A1 (en) |
| AU (1) | AU2012327247B2 (en) |
| BR (1) | BR112014014137A2 (en) |
| CA (1) | CA2858531C (en) |
| CL (1) | CL2014001559A1 (en) |
| CO (1) | CO7000779A2 (en) |
| CR (1) | CR20140321A (en) |
| DE (1) | DE112012005185T5 (en) |
| EA (1) | EA201491164A1 (en) |
| ES (1) | ES2647516T3 (en) |
| GB (1) | GB2512007B8 (en) |
| IL (1) | IL233025A0 (en) |
| MX (1) | MX352795B (en) |
| PE (1) | PE20142341A1 (en) |
| PH (1) | PH12014501231A1 (en) |
| PL (1) | PL2790685T3 (en) |
| SG (2) | SG11201403162XA (en) |
| TN (1) | TN2014000233A1 (en) |
| TW (1) | TW201338813A (en) |
| WO (1) | WO2013088254A1 (en) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| DE102006054731B4 (en) | 2006-11-21 | 2013-02-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system for administration of the active ingredient buprenorphine and use thereof in pain therapy |
| MX354603B (en) | 2007-05-25 | 2018-03-13 | Indivior Uk Ltd | Sustained delivery formulations of risperidone compounds. |
| GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| EP2729148A4 (en) | 2011-07-06 | 2015-04-22 | Parkinson S Inst | COMPOSITIONS AND METHODS FOR TREATING SYMPTOMS IN PATIENTS WITH PARKINSON'S DISEASE |
| EP3936133A1 (en) | 2011-11-23 | 2022-01-12 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| WO2013086217A1 (en) | 2011-12-06 | 2013-06-13 | Masco Corporation Of Indiana | Ozone distribution in a faucet |
| SG11201403162XA (en) | 2011-12-12 | 2014-10-30 | Lohmann Therapie Syst Lts | Transdermal delivery system comprising buprenorphine |
| WO2013126552A1 (en) * | 2012-02-21 | 2013-08-29 | Auburn University | Buprenorphine nanoparticle composition and methods thereof |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| TW201431570A (en) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | Multi-day patch for the transdermal administration of rotigotine |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| EA201592246A1 (en) | 2013-06-04 | 2016-05-31 | Лтс Лохманн Терапи-Системе Аг | TRANSDERMAL DELIVERY SYSTEM |
| ES2694662T3 (en) | 2013-07-03 | 2018-12-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system with electronic component |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| CA2948220C (en) | 2014-05-20 | 2023-06-20 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system containing rotigotine |
| US11426359B2 (en) | 2014-05-20 | 2022-08-30 | Lts Lohmann Therapie-Systeme Ag | Method for adjusting the release of active agent in a transdermal delivery system |
| CA2948221C (en) * | 2014-05-20 | 2022-11-22 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an interface mediator |
| KR20170005819A (en) | 2014-05-22 | 2017-01-16 | 쎄러퓨틱스엠디, 인코퍼레이티드 | Natural combination hormone replacement formulations and therapies |
| WO2016123406A1 (en) | 2015-01-28 | 2016-08-04 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
| EA201792014A1 (en) | 2015-03-10 | 2018-01-31 | Родс Текнолоджис | ACETATE SALT BUPRENORPHINE AND METHODS FOR OBTAINING BUPRENORPHINE |
| EP3267875A4 (en) | 2015-03-12 | 2018-12-05 | Chrono Therapeutics Inc. | Craving input and support system |
| EP3067050A1 (en) | 2015-03-13 | 2016-09-14 | Acino AG | Transdermal therapeutic system with an overtape comprising two adhesive layers |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| JP2018526415A (en) * | 2015-09-14 | 2018-09-13 | アムニール ファーマシューティカルズ エルエルシー | Transdermal delivery system |
| CN115093008B (en) | 2015-12-21 | 2024-05-14 | 德尔塔阀门公司 | Fluid delivery system including a sterilizing device |
| AU2017239645A1 (en) | 2016-04-01 | 2018-10-18 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| WO2018129304A1 (en) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
| WO2019064026A1 (en) | 2017-09-29 | 2019-04-04 | Orexo Ab | New pharmaceutical compositions |
| GB201716830D0 (en) | 2017-10-13 | 2017-11-29 | Cambrex Charles City Inc | New Process |
| US20210000756A1 (en) | 2018-03-13 | 2021-01-07 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system comprising a silicone acrylic hybrid polymer |
| CA3092752A1 (en) | 2018-03-13 | 2019-09-19 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system comprising a silicone acrylic hybrid polymer |
| EP3764998A1 (en) | 2018-03-13 | 2021-01-20 | LTS Lohmann Therapie-Systeme AG | Transdermal therapeutic system comprising a silicone acrylic hybrid polymer |
| CA3101966A1 (en) | 2018-05-29 | 2019-12-05 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| JP2022507660A (en) | 2018-11-16 | 2022-01-18 | モーニングサイド ベンチャー インベストメンツ リミテッド | Temperature-controlled transdermal drug delivery system |
| GB201904767D0 (en) | 2019-04-04 | 2019-05-22 | Orexo Ab | New pharmaceutical compositions |
| CN113952319A (en) * | 2021-11-30 | 2022-01-21 | 烟台大学 | Skeleton type transdermal patch containing buprenorphine and preparation method thereof |
| CN114397411A (en) * | 2021-12-14 | 2022-04-26 | 苏州高迈药业有限公司 | Method for evaluating lidocaine dicarbazine cream |
| WO2024040897A1 (en) * | 2022-08-24 | 2024-02-29 | 新领医药技术(深圳)有限公司 | Transdermal patch of thalidomide or analogue thereof and preparation method therefor |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US119585A (en) * | 1871-10-03 | Improvement in horse-collars and hames | ||
| US3474101A (en) | 1960-09-05 | 1969-10-21 | Reckitt & Sons Ltd | Thebaine and oripavine derivatives |
| GB1136214A (en) | 1965-06-15 | 1968-12-11 | Reckitt & Sons Ltd | Thebaine and oripavine derivatives |
| US4806341A (en) | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
| CA2002299A1 (en) | 1988-11-10 | 1990-05-10 | Eugene G. Drust | Compositions for the transdermal delivery of buprenorphine salts |
| DE3939376C1 (en) | 1989-11-29 | 1991-05-08 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De | |
| US5240711A (en) | 1989-11-29 | 1993-08-31 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system comprising as active component buprenorphine |
| US5069909A (en) | 1990-06-20 | 1991-12-03 | Cygnus Therapeutic Systems | Transdermal administration of buprenorphine |
| US5635203A (en) * | 1994-09-29 | 1997-06-03 | Alza Corporation | Transdermal device having decreased delamination |
| DE4446600A1 (en) * | 1994-12-24 | 1996-06-27 | Lohmann Therapie Syst Lts | Transdermal absorption of active ingredients from supercooled melts |
| US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| DE19922662C1 (en) | 1999-05-18 | 2000-12-28 | Sanol Arznei Schwarz Gmbh | Transdermal therapeutic system (TTS) containing tolterodine |
| DE19958554C2 (en) | 1999-07-02 | 2002-06-13 | Lohmann Therapie Syst Lts | Microreservoir system based on polysiloxanes and ambiphilic solvents and their manufacture |
| HU229085B1 (en) | 1999-07-02 | 2013-07-29 | Lohmann Therapie Syst Lts | Microreservoir system on the basis of polysiloxanes and ambiphilic solvents |
| WO2001014336A1 (en) * | 1999-08-20 | 2001-03-01 | Nippon Kayaku Kabushiki Kaisha | Benzene derivatives substituted by aromatic ring and process for producing the same |
| BR0108379A (en) | 2000-02-08 | 2002-11-05 | Euro Celtique Sa | Controlled release compositions containing opioid agonist and antagonist, method for preparing a controlled release opioid analgesic formulation with increased analgesic potency and delivery system through the dermis for an opioid analgesic |
| JP4659943B2 (en) * | 2000-02-25 | 2011-03-30 | 帝三製薬株式会社 | Patch containing buprenorphine hydrochloride |
| US6844727B2 (en) * | 2000-06-28 | 2005-01-18 | Baker Hughes Incorporated | Method and apparatus of reducing ringing in a nuclear magnetic resonance probe |
| US6682757B1 (en) | 2000-11-16 | 2004-01-27 | Euro-Celtique, S.A. | Titratable dosage transdermal delivery system |
| JP2004525960A (en) * | 2001-02-16 | 2004-08-26 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Use of buprenorphine in the manufacture of transdermal delivery devices for the treatment of urinary incontinence, especially urge incontinence |
| DE10141651B4 (en) | 2001-08-24 | 2007-02-15 | Lts Lohmann Therapie-Systeme Ag | Transdermal Therapeutic System (TTS) with the active ingredient Fentanyl and process for its preparation |
| DE10213772A1 (en) | 2002-03-27 | 2003-10-09 | Gruenenthal Gmbh | Cohesive unit of singular transdermal therapeutic systems |
| US20050118245A1 (en) | 2002-03-27 | 2005-06-02 | Wilsmann Klaus M. | Assembled unit consisting of individually separable, transdermal, therapeutic systems |
| US20050191340A1 (en) * | 2002-08-09 | 2005-09-01 | Gruenenthal Gmbh | Opioid-receptor antagonists in transdermal systems having buprenorphine |
| EP1526848B1 (en) * | 2002-08-09 | 2007-07-18 | Grünenthal GmbH | Opioid-receptor antagonists in transdermal systems having buprenorphine |
| ATE400258T1 (en) | 2002-12-13 | 2008-07-15 | Euro Celtique Sa | TRANSDERMAL BUPRENORPHINE DOSING SCHEME FOR PAIN RELIEF |
| RU2324372C2 (en) | 2003-03-25 | 2008-05-20 | Моринда, Инк. | Selective inhibition of estrogen production and activity in human |
| US8790689B2 (en) * | 2003-04-30 | 2014-07-29 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
| US7182955B2 (en) * | 2003-04-30 | 2007-02-27 | 3M Innovative Properties Company | Abuse-resistant transdermal dosage form |
| DE102004045599A1 (en) | 2004-09-17 | 2006-03-23 | Grünenthal GmbH | System for the sequential, transdermal administration of systemically active substances |
| DE102004062647A1 (en) | 2004-12-21 | 2006-06-29 | Kronotec Ag | Wood fiber insulation board or mat |
| DE102004062614B4 (en) | 2004-12-24 | 2011-12-29 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system with activatable supersaturation and controlled permeation promotion and process for its preparation |
| DE102006054731B4 (en) * | 2006-11-21 | 2013-02-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system for administration of the active ingredient buprenorphine and use thereof in pain therapy |
| DE102006054732B4 (en) | 2006-11-21 | 2010-12-30 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system with ion-pair microreservoirs |
| EP2366388A1 (en) | 2010-03-17 | 2011-09-21 | Ratiopharm GmbH | Non-occlusive transdermal therapeutic system for administering buprenorphine |
| SG11201403162XA (en) | 2011-12-12 | 2014-10-30 | Lohmann Therapie Syst Lts | Transdermal delivery system comprising buprenorphine |
| AU2013205080B2 (en) | 2012-12-12 | 2016-07-07 | Lts Lohmann Therapie-Systeme Ag | Transdermal Delivery System |
| EA201592246A1 (en) | 2013-06-04 | 2016-05-31 | Лтс Лохманн Терапи-Системе Аг | TRANSDERMAL DELIVERY SYSTEM |
-
2012
- 2012-12-12 SG SG11201403162XA patent/SG11201403162XA/en unknown
- 2012-12-12 PE PE2014000948A patent/PE20142341A1/en not_active Application Discontinuation
- 2012-12-12 ES ES12826670.7T patent/ES2647516T3/en active Active
- 2012-12-12 MX MX2014007020A patent/MX352795B/en active IP Right Grant
- 2012-12-12 JP JP2014546672A patent/JP6289378B2/en active Active
- 2012-12-12 EA EA201491164A patent/EA201491164A1/en unknown
- 2012-12-12 SG SG10201604754VA patent/SG10201604754VA/en unknown
- 2012-12-12 PL PL12826670T patent/PL2790685T3/en unknown
- 2012-12-12 CN CN201280069476.XA patent/CN104114161A/en active Pending
- 2012-12-12 AP AP2014007779A patent/AP4036A/en active
- 2012-12-12 CN CN201711075001.2A patent/CN107669662A/en active Pending
- 2012-12-12 US US14/364,192 patent/US20140363487A1/en not_active Abandoned
- 2012-12-12 GB GB1412385.5A patent/GB2512007B8/en active Active
- 2012-12-12 TW TW101146918A patent/TW201338813A/en unknown
- 2012-12-12 EP EP12826670.7A patent/EP2790685B1/en active Active
- 2012-12-12 DE DE112012005185.8T patent/DE112012005185T5/en not_active Ceased
- 2012-12-12 CA CA2858531A patent/CA2858531C/en active Active
- 2012-12-12 KR KR1020147019186A patent/KR102014565B1/en active Active
- 2012-12-12 AU AU2012327247A patent/AU2012327247B2/en not_active Ceased
- 2012-12-12 AR ARP120104673A patent/AR089201A1/en unknown
- 2012-12-12 BR BR112014014137A patent/BR112014014137A2/en not_active Application Discontinuation
- 2012-12-12 WO PCT/IB2012/002973 patent/WO2013088254A1/en active Application Filing
-
2014
- 2014-05-28 TN TNP2014000233A patent/TN2014000233A1/en unknown
- 2014-05-30 PH PH12014501231A patent/PH12014501231A1/en unknown
- 2014-06-08 IL IL233025A patent/IL233025A0/en unknown
- 2014-06-12 CL CL2014001559A patent/CL2014001559A1/en unknown
- 2014-07-04 CR CR20140321A patent/CR20140321A/en unknown
- 2014-07-11 CO CO14149730A patent/CO7000779A2/en unknown
-
2016
- 2016-01-11 US US14/992,122 patent/US9549903B2/en active Active
- 2016-10-07 JP JP2016198650A patent/JP2017036304A/en active Pending
- 2016-10-10 US US15/289,507 patent/US20170049713A1/en not_active Abandoned
-
2020
- 2020-01-31 US US16/778,920 patent/US20200306204A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014501231A1 (en) | Transdermal delivery system comprising buprenorphine | |
| GB2529789A (en) | Transdermal Delivery system | |
| PH12015501169A1 (en) | Transdermal delivery system | |
| BR112012032579A2 (en) | "diabetes therapy" | |
| MY163809A (en) | Transdermal drug delivery system containing donepezil | |
| PH12012501741A1 (en) | Treatment of lupus arthritis using laquinimod | |
| WO2011157416A3 (en) | Transdermal administration of memantine | |
| MX2011013201A (en) | Compositions for treating drug addiction and improving addiction-related behavior. | |
| NZ611920A (en) | Percutaneous absorption preparation containing rivastigmine | |
| MX2016009493A (en) | Abuse and misuse deterrent transdermal systems. | |
| AR092820A1 (en) | SYSTEMS AND METHODS TO TREAT AN ADVERSE ADVERSE PHARMACODYNAMIC RESPONSE, DOSE UNIT, KIT | |
| EA201400628A1 (en) | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE INTRODUCTION OF FENTANILE OR ITS ANALOGUE | |
| PH12016500666A1 (en) | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome | |
| UA116636C2 (en) | Transdermal formulation containing cox inhibitors | |
| MY166972A (en) | Transdermal delivery system containing galantamine or salts thereof | |
| HK1220125A1 (en) | Transdermal formulations of laquinimod | |
| ECSP14008829A (en) | TRANSDERMAL ADMINISTRATION SYSTEM | |
| Huilaja | Allergic contact dermatitis following transdermal administration: 3 case reports | |
| UA70336U (en) | Method for treating angina pectoris |